antiplatelet therapy

Spartan Bioscience has gained a CE IVD Mark for its Spartan RX CYP2C19 point-of-care test to guide antiplatelet treatment. Meanwhile, the firm is planning a US regulatory filing in 2011.

Although several studies have shown that carriers of CYP2C19 alleles do not respond to Plavix as well as non-carriers, and the FDA has updated the drug's label to notify physicians of the role of these alleles in Plavix metabolism, the assay's label specifically notes that "the INFINITI CYP2C19 Assay is not intended to be used to predict drug response or non-response."

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.